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
 
Abstract— Medical datasets are usually affected by several 
problems, such as missing values, inconsistencies, 
redundancies, that can influence the data mining process and 
the extraction of useful knowledge. For these reasons, a 
preprocessing phase should be performed for improving the 
overall quality of data and, consequently, of the information 
that may be discovered from them. In this study we applied five 
steps of data preprocessing to improve the quality of a large 
dataset derived from a multicenter clinical trial. Our dataset 
included 298 patients enrolled in a prospective, multicenter, 
clinical trial, characterized by 22 input variables and one class 
variable (MIPI value). In particular, data coming from 
different medical centers were firstly integrated to obtain a 
homogeneous dataset. The latter was normalized to scale all 
variables into smaller and similar intervals. Then, all missing 
values were estimated by means of an imputation step. The 
complete dataset was finally discretized and reduced to remove 
redundant variables and decrease the amount of data to be 
managed.  The improvement of data quality after each step was 
evaluated by means of the patients’ classification accuracy 
using the KNN classifier. Our results showed that the proposed 
pipeline produced an increment of more than 20% of the 
classification performances. Moreover, the highest growth of 
accuracy was obtained after missing value imputation, whereas 
the discretization and feature selection steps allowed for a 
significant reduction of variables to be managed, without any 
deterioration of the information contained in data. 
I. INTRODUCTION 
Clinical trials are clinical researches designed to produce 
new knowledge about a certain disease, drug or treatment [1] 
During these studies, a huge amount of data is collected 
about participants, therapies, clinical procedures, outcomes, 
adverse events and so on. Therefore, several variables (in 
some cases higher than the number of participants) are 
associated to each single patient enrolled in the study and all 
of them may contribute for a complete patient’s assessment.  
The analysis of the datasets obtained from clinical trials 
requires automatic techniques and methodologies able to 
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retrieve informative patterns drown in data and to extract new 
medical knowledge. The term Data Mining (DM) identifies a 
set of tools for searching for hidden patterns of interest in 
large and multivariate datasets [2]. The applications of DM 
techniques in the medical field range from outcome 
prediction and patient classification [3] to image and signal 
analysis [4,5]. Furthermore, in recent years, several 
researches focused the attention on data derived from 
genomic medicine and molecular biology [6]. Exhaustive 
reviews of clinical DM applications can be found in [6–8]. 
Even if it is usually used as a synonym of Knowledge 
Discovery in Databases (KDD), DM constitutes only one 
step in the complex KDD process that aims to “extracting 
high-level knowledge from low-level data in the context of 
large datasets” [9]. In the wider scenario of KDD, a 
preprocessing phase should be performed before the 
application of DM tools, for improving the overall quality of 
data and, consequently, of the information that might be 
discovered from them [10]. Poor quality of the collected 
clinical data, in terms of incomplete, incorrect or improper 
values, can produce detrimental consequences: as an 
example, incorrect calculation of outcome prediction might 
lead to an improper medical treatment for the patient [11]. 
This means that “quality decision must be based on quality 
data” [12].  
Data preprocessing techniques can be grouped into four 
classes, according to the problem they face with [13]. Data 
integration allows for merging data from multiple sources 
(for example those derived from multicenter clinical trials) 
into a homogeneous dataset, reducing inconsistencies. Data 
transformation techniques transform or consolidate data into 
forms that are appropriate for the DM processing. Two 
examples of data transformation methods are normalization, 
in which variables presenting very large and different ranges 
are scaled into similar intervals, and discretization, where the 
raw values of a numeric attribute are replaced by interval 
labels.  Data cleaning (or data cleansing) is usually applied 
to handle missing values (MVs), remove noise and correct 
inconsistencies in data. Finally, data reduction reduces 
dataset size by eliminating redundant and irrelevant variables, 
without any loss of useful information. These four 
approaches can be applied individually or combined among 
them in order to solve several issues. 
The aim of this study is to improve the data quality of a 
large dataset related to a prospective, multicenter clinical trial 
enrolling patients affected by mantle cell lymphoma (MCL).   
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II. MATERIALS AND METHODS 
A. Clinical Trial, Population and Dataset Description 
Data used in this study were collected from a phase III, 
multicenter, open-label, randomized, controlled trial aiming 
to determine the efficacy and safety of Lenalidomide 
(Revlimid®) as maintenance therapy versus observation in 
younger (< 65 years) patients affected by MCL and treated 
with high-dose immunochemoterapy and autologous stem 
cell transplantation as first-line therapy (FIL-MCL0208 trial, 
NCT02354313 [14]). The study was conducted in accordance 
with the Declaration of Helsinki and all the patients provided 
written informed consent for the collection and the research 
usage of clinical and biological data.  
Forty-eight Italian medical centers were actively involved 
in the trial, for a total of 300 enrolled patients (age: 55±8 
years). During the clinical trial several variables or features 
(more than 100) were acquired (derived from the compilation 
by the clinical centers of the electronic case report forms, 
eCRFs), describing the patient status at the diagnosis and at 
different time points. Among this huge number of variables, 
in this study we focused the attention on those derived from 
main clinical features, classical laboratory and pathological 
data, and several molecular data (derived from ancillary, 
biological investigations) recorded at the diagnosis of the 
disease. For each patient the corresponding MIPI (MCL 
international prognostic index) [15] value was assigned. MIPI 
is a prognostic index of overall survival that groups patients 
into 3 classes (1: low risk, 2: intermediate risk, 3: high risk) 
based on four independent clinical variables: age, ECOG 
(Eastern Cooperative Oncology Group) performance status 
[16], lactate dehydrogenase (LDH), and leukocyte count 
(WBC). According to the MIPI, 182 patients were classified 
as low risk subjects, 73 intermediate risk subjects and 43 high 
risk subjects. For two patients it was not possible to calculate 
MIPI, due to missing values in one of the four required 
variables. As some of the applied algorithms for quality 
improvement were supervised with the MIPI class, we 
decided to discard the four clinical variables determining the 
MIPI, as they could bias the final results. The definitive list 
of the 22 continuous input variables considered for each 
patient is reported in the first two columns of Table I. 
Therefore, our initial dataset contained 298 subjects 
characterized by 22 input variables and one class variable 
(MIPI value).  
B. Data Quality Improvement 
From a preliminary analysis of the collected data from the 
eCRF several problems were observed. Firstly, one variable 
(ß2) was measured using several devices having different 
thresholds for discriminating between normal and altered 
values. Then, the considered input features were associated to 
clinical parameters, with values ranges that are different one 
to the other. Moreover, many input values were missing. 
Finally, we might hypothesize that some of the acquired input 
variables can be irrelevant or redundant in impacting the 
patients’ outcome. Consequently, we proposed a process for 
data quality improvement based on 5 steps, each aiming to 
solve one of the problems previously described. 
 
 
 Step 1: Data Integration 
Data integration is usually necessary for data coming 
from multiple sources, each collecting parameters with 
different orders of magnitude, units of measurement, or 
ranges of validity. In our case, the input variable ß2 is a 
laboratory measurement whose values were obtained with 
different devices according to the medical center responsible 
for the measurement. This means that the threshold for 
discriminating between normal and altered values 
(ß2_threshold) was different according to the center and it 
was provided together with the patient’s ß2 value. In order to 
obtain a homogeneous ß2 variable, we redefined each value 
(ß2_value) as: (ß2_value-ß2_threshold)/ ß2_threshold. In 
this way normal ß2 measurements (that means under the 
threshold) were represented with negative values, 
whereas positive values were associated to altered ß2 
measurements (that means above the threshold). 
TABLE I.   INPUT VARIABLES  DESCRIPTION 
Feature 
Name 
Description 
No of 
MVs 
FS 
Result 
Echo  Left ventricular ejection fraction by 
either bi-dimensional 
echocardiogram or cardiac 
scintigraphy [%] 
42  
PLTs Platelets or thrombocytes [109 per 
L] 
8  
Hb Hemoglobin [g/dL] 1 1 
ß2M ß2-microglobulin [mg/L] 60 1 
Protein Total amount of Albumin and 
Globulins [g/dL] 
19  
Albumin Serum albumin [g/dL] 37  
IgG Immunoglobulin G [g/L] 78 1 
IgA Immunoglobulin A [g/L] 78  
IgM Immunoglobulin M [g/L] 78  
AST Aspartate transaminase [U/L] 14  
ALT Alanine transaminase [U/L] 6  
gamma-GT Gamma-glutamyl transferase [U/L] 22  
Alkaline 
Phosph 
Alkaline phosphatase [U/L] 27  
Bilirubin Bilirubin [mg/dL] 20  
Creatinine Serum creatinine [mg/dL] 6  
qnt BM  Quantitative evaluation of the 
molecular tumor marker in the 
diagnostic bone marrow sample 
161 1 
qnt PB  Quantitative evaluation of the 
molecular tumor marker in the 
diagnostic peripheral blood sample 
154 1 
Ki-67 Antigen Ki-67 expression on 
diagnostic sample [%] 
27  
Flow BM Quantitative evaluation of the tumor 
invasion by Flow cytometric 
immune-phenotyping analysis in the 
diagnostic bone marrow sample 
17 1 
Flow PB Quantitative evaluation of the tumor 
invasion by Flow cytometric 
immune-phenotyping analysis in the 
diagnostic peripheral blood sample 
48  
BM 
Infiltration  
Quantitative evaluation of the tumor 
invasion by morphologic and 
immunochemistry analysis in the 
diagnostic bone marrow biopsy 
sample [%] 
71  
IgH 
Omology 
Omology of the monoclonal 
immunoglobulin heavy chain gene 
rearrangement to the germline 
sequence [%] 
86  
 
  
 Step 2: Data Transformation – Normalization 
Normalization is required for variables sets presenting 
very different ranges, above all when DM tools involving 
distance metrics are going to be used subsequently. In our 
dataset, each input feature was related to a different clinical 
parameter with its own range of admissible values. To obtain 
comparable variability intervals, we normalized every 
variable using the min-max scaling: (Var_value-
Var_min)/(Var_max-Var_min), where Var_min and 
Var_max are the minimum and the maximum values assumed 
for that variable, respectively. In this way, values between 0 
and 1 were obtained. 
 Step 3: Data Cleaning – Missing Values Imputation 
Handling of MVs is one of the most recurrent problems in 
medical datasets, due to missing manual input or examination 
results. As in our case the amount of MVs was very high for 
every input variable, it was not possible to follow the usually 
used approach of discarding subjects containing missing 
elements. Therefore, given a patient with a certain MIPI 
score and a MV for a specific input variable, we replaced this 
element with the median of the feature values calculated 
across all subjects within the same MIPI class. 
 Step 4: Data Transformation – Discretization 
In this study, a discretization step was introduced to 
transform continuous variables into discrete features, 
partitioning each range of values into a set of adjacent 
intervals. In general, three are the aims of discretization: to 
reduce noise due to small variations of values, to decrease the 
amount of values to be memorized and managed, and to 
improve the classification performances [17]. Moreover, in 
this case it was a mandatory phase for applying the tool for 
data reduction in the following step. The ChiMerge algorithm 
[18] was chosen and implemented in this study for 
discretization. It is a supervised and bottom-up method that 
discretizes each variable separately using the χ2 statistic. It 
iteratively merges adjacent elements until the χ2 value 
exceeds a defined threshold. In this work, the threshold is 
determined as the χ2 value for a significance level of 0.95 
and a number of degrees of freedom equal to the number of 
MIPI classes minus one, that is 2. 
 Step 5: Data Reduction – Feature Selection 
Feature selection (FS) identifies a group of methods for 
dimensionality reduction able to choose a subset of the 
original variables without any reduction of the amount of 
information contained in data. This is possible because only 
relevant and non-redundant features are selected according to 
some criteria, producing an increase of the learning accuracy 
and of result comprehensibility. The QuickReduct Algorithm 
(QRA) [19] was used in this study to select the most 
important features. It is a supervised tool based on the Rough 
Set Theory that allows for solving FS problems without 
generating all the possible subsets. QRA uses the dependency 
degree γR(D) value to measure the importance of a given 
subset of input features R with respect to the class attribute D. 
The main idea of the algorithm is to iteratively add to the 
actual features subset those attributes producing the largest 
increase in the dependency degree.  
C. Validation 
To validate the proposed pipeline and to prove the 
improvement of data quality, we assess the capability of the 
datasets obtained after each step to correctly classify the 
subjects involved in the study in the pre-existing MIPI risk 
class. Moreover, we compared these results with the 
classification accuracy reached by the initial raw dataset. 
The k-nearest neighbor (KNN) algorithm was used for the 
classification, as it is less influenced by the class imbalance 
than other classifiers. We have tested k values from 3 to 10 
and different distance metrics such as the Euclidean, the 
Chebyshev and the Manhattan distances. However, as the 
purpose of this study is not to classify the patients but only to 
measure the quality variation, here we reported the best 
results reached with k=7 and the Manhattan distance, even if 
similar results were obtained with the other parameters. The 
leave-one-out validation was employed for assessing the 
classification performances. 
III. RESULTS AND DISCUSSION 
Steps 1 and 2 of the proposed methodology allowed for 
obtaining a dataset in which all input variables showed 
homogeneous variability ranges. The number of MVs for 
each feature is reported in the third column of Table I. All 
these elements were imputed during step 3 and the complete 
dataset was used for the last two steps of the data quality 
improvement process. Once the dataset has been discretized 
in step 4, the FS algorithm was applied and the results in 
terms of selected features are showed in the last column of 
Table I (where “1” identifies a selected feature). As it 
emerges from the table, only six variables were selected in 
this phase: Hb, ß2M, IgG, qnt BM, qnt PB, Flow BM.  
Table II shows the results of the validation phase in terms 
of classification performances, using the initial dataset and 
after each step of the applied methodology. The percentage of 
subjects that are correctly, incorrectly or not classified (no 
majority of votes for a class is reached) by the KNN is 
presented. Analyzing the second column of Table II it can be 
observed that, even if the first two steps do not produce any 
significant variation of the performances with respect to the 
initial dataset, the MVs imputation (step 3) allows for 
increasing the percentage of correct classification of about 
20% with respect to step 2. Moreover, even if the variables 
discretization (step 4) slightly reduce the performances with 
respect to step 3, the FS method (step 5) produces a further 
improvement of the classification accuracy, meaning that the 
discarded variables represented a source of noise for the 
TABLE II.  VALIDATION RESULTS 
 
Patients 
correctly 
classified 
Patients 
incorrectly 
classified 
Patients 
not 
classified 
Initial 
dataset 
57.6% 31.9% 10.5% 
Step 1 57.2% 31.6% 11.2% 
Step 2 59.5% 32.2% 8.2% 
Step 3 79.3% 14.8% 5.9% 
Step 4 77.6% 16.8% 5.6% 
Step 5 81.9% 13.2% 4.9% 
 
  
identification of the patients’ risk class. An opposite behavior 
can be observed analyzing the number of incorrectly and not 
classified patients (last two columns of Table II). These 
percentages are considerably reduced after MVs imputations, 
meaning that the missing information is necessary for a 
correct identification of the patient risk class. Furthermore, 
the last two steps don’t produce a significant deterioration of 
the performances.   
In Table III we report the confusion matrix obtained at the 
end of the data quality improvement process. Each 
percentage is calculated with respect to the total number of 
subjects belonging to a specific MIPI class. As it emerges 
from the table, the highest accuracy is obtained for the low 
risk class (92.83%), that is the largest group of subjects. 
Although the KNN slightly feels the effects of the class 
imbalance, we can suppose that this class should influence 
the classifier training and, as a consequence, the classification 
accuracy. The lowest performance is returned for the 
intermediate risk class (65.8%). From the MIPI point of view, 
this class is assigned to patients obtaining a score between 5.7 
and 6.2, which is a very tight interval. This can lead to a 
probable misclassification of borderline subjects that can 
affect also the classifier accuracy.  
IV. CONCLUSION 
In this study we focused the attention on the phase of data 
preprocessing with the aim of improving the quality of data 
and of the knowledge retrieved from them. We applied a 
five-step pipeline for increasing the quality of a dataset 
obtained from a multicenter clinical trial on MCL patients. 
We evaluate the quality improvement obtained after each step 
in terms of patients’ classification accuracy.  
Our results showed that the imputation of MVs is the 
phase that mostly produces an increment of the data quality 
and classification performances. Moreover, the data 
discretization and the FS allow for a significant reduction of 
the amount of elements and variables to be managed, without 
any deterioration of the information contained in data. 
Finally, it is important to highlight that the FS algorithm used 
in this study is supervised with the class variable. This means 
that the six selected variables, that are not used for the MIPI 
calculation, are the most important for discriminate patients 
according to their MIPI value, as it was confirmed also by the 
classification results. 
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TABLE III.  FINAL CONFUSION MATRIX 
  Predicted Class 
  
Not 
Classified 
Low 
Risk 
Intermed
iate Risk 
High 
Risk 
A
c
tu
a
l 
C
la
ss
 Low 
Risk 
2.2% 92.3% 1.6% 3.8% 
Intermedi
ate Risk 
2.7% 21.9% 65.8% 9.6% 
High 
Risk 
7.0% 7.0% 9.3% 76.7% 
 
